Renalis
Chicago, US · Founded 2016 · Illinois corporation · 1 known investors
Find your way into Renalis
1 people in our graph share verified history with the Renalis team — schools, employers, funds. One of them is your warm intro.
Renalis develops prescription digital therapeutics (PDTs), software applications that deliver evidence-based therapeutic interventions to patients under a clinician's care to prevent or treat medical disorders. The products are developed like pharmaceuticals, undergoing clinical trials and FDA clearance, and are available only by clinician prescription.
Founders & leadership
Renalis was founded in 2016 by Missy Lavender.
ML
Missy LavenderinChief Executive Officer & FounderMissy Lavender is an executive with experience in digital health and launching both for-profit and non-profit organizations. She has held roles in investor relations at public real estate development companies and in banking and investment banking.
Investors · 1
Reported raises · per SEC filings
Form D private placements$745K disclosed across 3 rounds · 2019–2023
▶$25KraisedAug 2023 · 10 investors · OtherRule 506(b)
▶$25KraisedAug 2023 · 10 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Missy LavenderExecutive Officer
- Offering amount
- $500K
- Amount sold
- $25K
- First sale
- Aug 2023
- Incorporated
- Corporation, Illinois
- Federal exemptions
- 06b
▶$700KraisedSep 2021 · 11 investors · OtherRule 506(b)
▶$700KraisedSep 2021 · 11 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Missy LavenderExecutive Officer, Director
- Offering amount
- $700K
- Amount sold
- $700K
- First sale
- Aug 2021
- Incorporated
- Limited Liability Company, Illinois
- Federal exemptions
- 06b
▶$20KraisedSep 2020 · 10 investors · OtherRule 506(b)
▶$20KraisedSep 2020 · 10 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Missy LavenderExecutive Officer
- Offering amount
- $1.3M
- Amount sold
- $20K
- First sale
- Dec 2019
- Incorporated
- Limited Liability Company, Illinois, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 9
by search overlap
Borealisbio6 shared keywordsBorealis develops RNA medicines to treat kidney diseases. The company was founded by the team behind Chinook Therapeutics, which Novartis acquired in 2023, and focuses on kidney disease indications with unmet medical need.
Chrysalis5 shared keywordsChrysalis is a company builder that develops software using timely data to create digital-meets-personal customer moments, applied in sectors such as retail and hospitality. Founded on a self-organization, people-first philosophy, it builds and operates multiple product companies.
Resalis Therapeutics5 shared keywordsResalis Therapeutics develops antisense oligonucleotide therapies targeting microRNA pathways for metabolic disorders. The company is advancing RES-010, a treatment candidate for obesity, fatty liver disease, and related metabolic disorders.
Gradalis5 shared keywordsGradalis develops Vigil, a patient-specific immunotherapy studied in research and clinical trials for treating ovarian cancer, with potential use in other solid tumors. The therapy can be used on its own or alongside other cancer treatments.
株式会社モダリス5 shared keywordsModalis Therapeutics develops therapeutics using CRISPR gene-editing technology and provides its platform technology for drug development. It operates in the biotechnology sector.
Zentalis5 shared keywordsZentalis is a biopharmaceutical company developing azenosertib and other pipeline assets, seeking strategic partnerships to advance drug development and expand market reach globally.
Aurealistherapeutics5 shared keywordsAurealis Therapeutics is a Swiss-Finnish clinical-stage company developing multi-target bacterial gene therapies based on genetically engineered Lactococcus cremoris, using a modular platform that produces multiple human therapeutic proteins directly in diseased tissue. Its therapies target chronic wounds, cancer, and inflammatory diseases, with a lead product for diabetic foot ulcers.
Chrysalis Biotherapeutics5 shared keywordsChrysalis Biotherapeutics is a clinical-stage biopharmaceutical company developing peptide therapeutics, led by its drug candidate TP508 (Rusalatide acetate, Chrysalin), which activates endothelial and stem cells to repair tissue after severe viral infection or nuclear radiation. Its immediate target is treating mild to moderate acute respiratory distress syndrome (ARDS) to reduce mortality.
Genialis4 shared keywordsGenialis is a precision oncology company that applies data analysis to help drug developers understand mechanisms of action, resistance, and patient stratification for cancer therapies. It supports pharmaceutical partners in advancing molecules through clinical trials toward becoming effective medicines.
Companies competing with Renalis for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Renalis do?
- Renalis develops prescription digital therapeutics (PDTs), software applications that deliver evidence-based therapeutic interventions to patients under a clinician's care to prevent or treat medical disorders. The products are developed like pharmaceuticals, undergoing clinical trials and FDA clearance, and are available only by clinician prescription.
- Who founded Renalis?
- Renalis was founded by Missy Lavender in 2016.
- Who are Renalis's investors?
- Renalis's investors include Jumpstart Ventures.
- How much funding has Renalis raised?
- Renalis has disclosed $745K raised across 3 rounds.
- Where is Renalis headquartered?
- Renalis is headquartered in Chicago, US.